The anti-CD20 monoclonal antibody rituximab is approved for the treatment of many diseases, including non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and rheumatoid arthritis [31]. The gene discussed is MS4A1; the disease is B-cell chronic lymphocytic leukemia.